

Lampropoulos Justin J.  
Form 4  
November 20, 2018

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Lampropoulos Justin J.

2. Issuer Name and Ticker or Trading Symbol  
MERIT MEDICAL SYSTEMS INC  
[MMSI]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
1600 WEST MERIT PARKWAY  
(Street)

3. Date of Earliest Transaction  
(Month/Day/Year)  
11/16/2018

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
EVP GLOBAL SALES, MKTG & STGY

SOUTH JORDAN, UT 84095

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price                                      |
| Common Stock, No Par Value      | 11/16/2018                           |  | M                              |   | 20,000  | A  | \$ 12.06                                   |
| Common Stock, No Par Value      | 11/16/2018                           |  | S                              |   | 20,000  | D  | \$ 61.01<br><u>(1)</u>                     |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Edgar Filing: Lampropoulos Justin J. - Form 4

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Underlying Security (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
| Non-qualified stock options (right to buy) | \$ 13.14   |                                      |  |                                |   | 07/31/2014 <sup>(2)</sup> 07/31/2020                     | Common Stock                                      |
| Non-qualified stock options (right to buy) | \$ 12.06   | 11/16/2018                           |  | M                              | 20,000  | 10/04/2015 <sup>(3)</sup> 10/04/2021                     | Common Stock                                      |
| Non-qualified stock options (right to buy) | \$ 17.27   |                                      |  |                                |   | 02/13/2016 <sup>(4)</sup> 02/13/2022                     | Common Stock                                      |
| Non-qualified stock options (right to buy) | \$ 16.05   |                                      |  |                                |   | 01/28/2017 <sup>(5)</sup> 01/28/2023                     | Common Stock                                      |
| Non-qualified stock options (right to buy) | \$ 28.2  |                                      |  |                                |   | 04/14/2018 <sup>(6)</sup> 04/14/2024                     | Common Stock                                      |
| Non-qualified stock options (right to buy) | \$ 44.8  |                                      |  |                                |   | 03/02/2019 <sup>(7)</sup> 03/02/2025                     | Common Stock                                      |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |         |                               |
|---|---------------|-----------|---------|-------------------------------|
|   | Director      | 10% Owner | Officer | Other                         |
| Lampropoulos Justin J.<br>1600 WEST MERIT PARKWAY<br>SOUTH JORDAN, UT 84095 |               |           |         | EVP GLOBAL SALES, MKTG & STGY |

## Signatures

Brian G. Lloyd,  
Attorney-in-Fact

11/20/2018

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$60.155 to \$61.400, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- (1) Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  - (2) Became exercisable in equal annual installments of 20% commencing on 07/31/2014.
  - (3) Becomes exercisable in equal annual installments of 20% commencing on 10/04/2015.
  - (4) Becomes exercisable in equal annual installments of 20% commencing on 02/13/2016.
  - (5) Becomes exercisable in equal annual installments of 20% commencing on 01/28/2017.
  - (6) Becomes exercisable in equal annual installments of 20% commencing on 04/14/2018.
  - (7) Becomes exercisable in equal annual installments of 20% commencing on 03/02/2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.